{"slideshow_credits": null, "snippet": "Two new powerful drugs have been approved. The question is whether the benefits will outweigh the long-term costs.", "abstract": "Editorial expresses concern about very high price of cholesterol drugs Praluent and Repatha, which could outweigh their benefits; notes that both drugs cost about $14,000 per month to take, and most patients prescribed drugs will need to take them for lifetime; underscores necessity for more competition to drive down prices, and for insurers to push pharmaceutical companies for larger discounts.", "section_name": "Opinion", "print_page": "26", "document_type": "article", "byline": {"person": [], "original": "By THE EDITORIAL BOARD", "organization": "THE EDITORIAL BOARD"}, "web_url": "http://www.nytimes.com/2015/09/08/opinion/the-price-for-lowering-cholesterol.html", "lead_paragraph": "Two new powerful drugs have been approved. The question is whether the benefits will outweigh the long-term costs.", "headline": {"print_headline": "The Price for Lowering Cholesterol", "main": "The Price for Lowering Cholesterol", "content_kicker": "Editorial", "kicker": "Editorial"}, "_id": "55ee8c6338f0d85bc57750e9", "word_count": "507", "multimedia": [{"height": 126, "url": "images/2015/09/08/opinion/08tue2web/08tue2web-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2015/09/08/opinion/08tue2web/08tue2web-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 427, "url": "images/2015/09/08/opinion/08tue2web/08tue2web-articleLarge.jpg", "legacy": {"xlarge": "images/2015/09/08/opinion/08tue2web/08tue2web-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "427"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2015/09/08/opinion/08tue2web/08tue2web-thumbStandard.jpg", "legacy": {"thumbnail": "images/2015/09/08/opinion/08tue2web/08tue2web-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2015-09-08T00:00:00Z", "source": "The New York Times", "news_desk": "Editorial", "keywords": [{"name": "subject", "value": "Editorials", "is_major": "Y", "rank": "1"}, {"name": "subject", "value": "Cholesterol", "is_major": "Y", "rank": "2"}, {"name": "subject", "value": "Praluent (Drug)", "is_major": "N", "rank": "3"}, {"name": "subject", "value": "Repatha (Drug)", "is_major": "N", "rank": "4"}, {"name": "subject", "value": "Prices (Fares, Fees and Rates)", "is_major": "N", "rank": "5"}, {"name": "subject", "value": "Health Insurance and Managed Care", "is_major": "N", "rank": "6"}, {"name": "subject", "value": "Statins (Cholesterol-Lowering Drugs)", "is_major": "N", "rank": "7"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "8"}], "blog": [], "subsection_name": null, "type_of_material": "Editorial"}